INDUSTRY NEWS International Society for Cellular Therapy (ISCT) Launches Inaugural Cell Therapy Commercial Development Focus Group on Peripheral Vascular Disease In keeping with its commitment to connect industry, regulatory experts, therapeutic societies and translational centers to advance emerging cellular therapies, ISCT announced its first commercial development focus group addressing Cell Therapies for Peripheral Vascular Disease. [Reuters] Héma-Québec Selects Pilgrim Software to Manage Enterprise-Wide Quality and Compliance Processes Pilgrim Software, Inc. announced that Héma-Québec, the Canadian service organization that manages the collection and distribution of blood and blood products for the Province of Québec, has selected Pilgrim to manage key quality-related processes across its province-wide operations. [Pilgrim Software, Inc. Press Release] NYU Langone Medical Center Establishes The Rita J. and Stanley H. Kaplan Stem Cell/Bone Marrow Transplant Center NYU Langone Medical Center announced the opening of The Rita J. and Stanley H. Kaplan Stem Cell/Bone Marrow Transplant Center (Kaplan Center), dedicated to providing stem cell transplants and comprehensive in-patient and out-patient care for adult and pediatric patients with hematologic cancers. [NYU Langone Medical Center Press Release] First Cord Blood Collection Center in the Midlands Cord blood donation is now taking place at Leicester’s Hospitals thanks to the development of a new Anthony Nolan cord blood collection centre, the first of its kind outside the south east of England. [University Hospitals of Leicester Press Release] Consensus Statement: Statement on Policies and Practices Governing Data and Materials Sharing and Intellectual Property in Stem Cell Science Tension is increasing between fairly new and pervasive policies and practices governing data and materials sharing and intellectual property in science, and norms of openness and free exchange. While intellectual property rights can bring private investment into areas underfunded by governments and help bridge gaps between scientific invention or discovery and useful technologies, some new and emerging policies and practices risk slowing innovation in research and development and skewing attention toward large markets, to the disadvantage of small markets, such as those for rare diseases and in some emerging economies. [Hinxton Group]
|